Alpha-glucosidase (Bacillus) (AG)

Bacillus alpha-glucosidase is a bacterial enzyme belonging to the glycoside hydrolase family that catalyzes the release of alpha-glucose from the non-reducing ends of oligosaccharides and polysaccharides [UniProt: P21332]. While it is a bacterial protein, it serves as a primary in vitro model and screening target in the development of alpha-glucosidase inhibitors (AGIs) for the treatment of type 2 diabetes mellitus [PubMed: 25613724]. By inhibiting this enzyme, the breakdown of complex carbohydrates into simple sugars is delayed, which effectively lowers postprandial blood glucose levels [StatPearls: NBK557848]. In clinical practice, drugs like acarbose and miglitol target the human intestinal counterparts of this enzyme, but the Bacillus variant is highly valued in pharmacological research for its structural stability and ease of purification [PubChem: 41774]. Therapeutic challenges associated with inhibiting this class of enzymes primarily involve gastrointestinal side effects resulting from the fermentation of undigested carbohydrates in the colon [PubMed: 11078440]. Consequently, it remains a cornerstone of drug discovery efforts aimed at managing metabolic disorders and exploring novel natural product inhibitors.

Other names

Maltase [UniProt: P21332]α-D-glucoside glucohydrolase [UniProt: P21332]Glucoside hydrolase [UniProt: P21332]Alpha-1,4-glucosidase [UniProt: P21332]Bacillus stearothermophilus alpha-glucosidaseBacillus subtilis alpha-glucosidase

Competitive inhibition of the enzyme's active site, preventing the hydrolysis of oligosaccharides and disaccharides into absorbable glucose [PubChem: 41774].